Article Sidebar
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
Nevapine: An option for preventing as well as treating paediatric HIV infection
Abstract
In Brief
Nevirapine belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI) of HIV. It reduces perinatal HIV transmission when administered as a 2-dose regimen, 1 dose to pregnant women during labour and 1 dose to the new born infant within 72 hours of birth. This nevirapine regimen was more effective than a short course of intrapartum and neonatal zidovudine in a randomised trial in breastfeeding women in Uganda. The 2-dose mother-infant nevirapine regimen is well tolerated and is more cost effective and easier to administer in resource-poor settings than zidovudine. In the US, guidelines for the prevention of perinatal HIV transmission suggest the use of the 2-dose nevirapine regimen as one of the possible treatment options for pregnant women who have received no previous antiretroviral therapy and whose infection is diagnosed late in pregnancy or during labour.
Data concerning the use of nevirapine for the treatment of children with established HIV infection are still limited. It should only be used in combination with at least 2 other antiretroviral agents. In small numbers of patients nevirapine-containing triple antiretroviral combination regimens have produced reductions of HIV RNA both in plasma and the CSF.
African Health Sciences 2001; 1(1): 32-35.
